Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial

被引：0

作者：

Craig, T. J. ^{[1
]}

Reshef, A. ^{[2
]}

Lumry, W. R. ^{[3
]}

Saguer, I. Martinez ^{[4
]}

Jacobs, J. S. ^{[5
]}

Yang, W. H. ^{[6
]}

Aygoren-Pursun, E. ^{[7
]}

Keith, P. K. ^{[8
]}

Busse, P. ^{[9
]}

Magerl, M. ^{[10
]}

Feuersenger, H. ^{[11
]}

Bica, M. A. ^{[11
]}

Glassman, F. ^{[12
]}

Pragst, I. ^{[11
]}

Levy, D. S. ^{[13
]}

机构：

[1] Penn State Univ, Dept Med & Pediat, Allergy Asthma & Immunol, Hershey, PA USA

[2] Barzilai Univ Hosp, Allergy & Immunol Angioedema Ctr, Ashqelon, Israel

[3] AARA Res Ctr, Dallas, TX USA

[4] HZRM Haemophilia Ctr Rhein Main, Morfelden Walldorf, Germany

[5] Allergy & Asthma Clin Res, Walnut Creek, CA USA

[6] Univ Ottawa, Ottawa Allergy Res Corp, Dept Med, Ottawa, ON, Canada

[7] Klinikum Johann Wolfgang Goethe Univ, Klin Kinder & Jugendmed, Frankfurt, Germany

[8] McMaster Univ, Med Ctr Site, Hamilton, ON, Canada

[9] Mt Sinai, New York, NY USA

[10] Charite Univ Med Berlin, Inst Allergol, Fraunhofer Inst Translat Med & Pharmacol ITMP All, Berlin, Germany

[11] CSL Behring Innovat GmbH, Marburg, Germany

[12] CSL Behring, King Of Prussia, PA USA

[13] Univ Calif Irvine, Div Allergy & Immunol, Irvine, CA USA

来源：

ALLERGOLOGIE | 2023年 / 46卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

P8.10

引用

页码：560 / 561

页数：2

共 50 条

[1] Garadacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial
Reshef, A.
Magerl, M.
Saguer, I. Martinez
Bernstein, J. A.
Farkas, H.
Yang, W. H.
Jacobs, J. S.
Li, P. Hei
Lumry, W. R.
Aygoeren-Puersuen, E.
Ohsawa, I.
Katelaris, C.
Longhurst, H.
Hakl, R.
Guilarte, M.
Stroes, E. S. G.
Feuersenger, H.
Bica, M. A.
Jacobs, I.
Craig, T. J.
ALLERGOLOGIE, 2023, 46 (08) : 561 - 562
[2] Garadacimab For Hereditary Angioedema Prophylaxis In Adolescents: Efficacy And Safety From The Phase 3 (VANGUARD) Study And Open-Label Extension (Second Interim Analysis)
Jacobs, Joshua
Magerl, Markus
Martinez-Saguer, Inmaculada
Li, Huamin
Bernstein, Jonathan
Hsu, Connie
Sitz, Karl
Wieman, Lolis
Feuer-Senger, Henrike
Pollen, Maressa
Reshef, Avner
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB6 - AB6
[3] Garadacimab for hereditary angioedema prophylaxis in adolescents: efficacy and safety from the VANGUARD Phase 3 and 3b open-label extension trial (first interim analysis)
Magerl, M.
Saguer, I. Martinez
Jacos, J. S.
Li, H.
Bernstein, J. A.
Hsu, C.
Sitz, K. V.
Pragst, I.
Feuersenger, H.
Wieman, L.
Pollen, M.
Rese, A.
ALLERGOLOGIE, 2023, 46 (08) : 562 - 562
[4] Integrated Safety And Efficacy Of Garadacimab For Hereditary Angioedema Prophylaxis Across 3 Clinical Trials: Phase 2, Pivotal Phase 3, And Open-Label Extension Studies
Craig, Timothy
Anderson, John
Jacobs, Joshua
Tachdjian, Raffi
Farkas, Henriette
Yang, William
Ohsawa, Isao
Pollen, Maressa
Lawo, John-Philip
Bica, Alex
Jacobs, Iris
Magerl, Markus
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB256 - AB256
[5] LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN- LABEL EXTENSION STUDY
Anderson, J.
Levy, D.
Sussman, G.
Jacobs, J.
Farkas, H.
Pollen, M.
Feuersenger, H.
Craig, T.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S5 - S5
[6] Long-term efficacy and safety of subcutaneous garadacimab for prophylaxis of hereditary angioedema attacks: Results from a multicentre phase 3 study and open-label extension
Magerl, M.
Reshef, A.
Farkas, H.
Li, H. H.
Jacobs, J. S.
Bernstein, J.
Yang, W.
Stroes, E. S.
Ohsawa, I.
Tachdjian, R.
Manning, M. E.
Lumry, W. R.
Saguer, I. Martinez
Aygoeren-Puersuen, E.
Ritchie, B.
Sussman, G. L.
Anderson, J.
Kawahata, K.
Suzuki, Y.
Staubach, P.
Treudler, R.
Feuersenger, H.
Jacobs, I.
Craig, T. J.
ALLERGY, 2023, 78 : 115 - 117
[7] Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study
Reshef, Avner
Hsu, Connie
Katelaris, Constance H.
Li, Philip H.
Magerl, Markus
Yamagami, Keiko
Guilarte, Mar
Keith, Paul K.
Bernstein, Jonathan A.
Lawo, John-Philip
Shetty, Harsha
Pollen, Maressa
Wieman, Lolis
Craig, Tim J.
ALLERGY, 2025, 80 (02) : 545 - 556
[8] Integrated safety and efficacy of garadacimab for hereditary angioedema prophylaxis across 3 clinical trials: phase 2, pivotal phase 3, and open- label extension studies
Magerl, M.
Craig, T. J.
Anderson, J.
Jacobs, J. S.
Tachdjian, R.
Farkas, H.
Yang, W. H.
Staubach, P.
Aygoeren-Puersuen, E.
Ohsawa, I.
Pollen, M.
Lawo, J. -P.
Bica, M. A.
Jacobs, I.
ALLERGOLOGIE, 2024, 47 (09)
[9] Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
Craig, Timothy J.
Levy, Donald S.
Reshef, Avner
Lumry, William R.
Martinez-Saguer, Inmaculada
Jacobs, Joshua S.
Yang, William H.
Ritchie, Bruce
Aygoeren-Puersuen, Emel
Keith, Paul K.
Busse, Paula
Feuersenger, Henrike
Bica, Mihai Alexandru
Jacobs, Iris
Pragst, Ingo
Magerl, Markus
LANCET HAEMATOLOGY, 2024, 11 (06): : e436 - e447
[10] A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design
Riedl, M.
Bernstein, J. A.
Craig, T.
Banerji, A.
Magerl, M.
Cicardi, M.
Longhurst, H. J.
Shennak, M.
Yang, W.
Schranz, J.
Baptista, J.
Busse, P.
ALLERGY, 2017, 72 : 598 - 599

← 1 2 3 4 5 →